{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Armas-Lopez L"],"funding":["NCI NIH HHS"],"pagination":["67056-67081"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5620156"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(40)"],"pubmed_abstract":["Several homeobox-related gene (HOX) transcription factors such as mesenchyme HOX-2 (MEOX2) have previously been associated with cancer drug resistance, malignant progression and/or clinical prognostic responses in lung cancer patients; however, the mechanisms involved in these responses have yet to be elucidated. Here, an epigenomic strategy was implemented to identify novel MEOX2 gene promoter transcription targets and propose a new molecular mechanism underlying lung cancer drug resistance and poor clinical prognosis. Chromatin immunoprecipitation (ChIP) assays derived from non-small cell lung carcinomas (NSCLC) hybridized on gene promoter tiling arrays and bioinformatics analyses were performed, and quantitative, functional and clinical validation were also carried out. We statistically"],"journal":["Oncotarget"],"pubmed_title":["Epigenomic study identifies a novel mesenchyme homeobox2-GLI1 transcription axis involved in cancer drug resistance, overall survival and therapy prognosis in lung cancer patients."],"pmcid":["PMC5620156"],"funding_grant_id":["R35 CA197449"],"pubmed_authors":["Ortiz-Quintero B","Avila-Moreno F","Pina-Sanchez P","Zuniga J","Arrieta O","Santillan-Doherty P","Christiani DC","Armas-Lopez L","de Alba EG"],"additional_accession":[]},"is_claimable":false,"name":"Epigenomic study identifies a novel mesenchyme homeobox2-GLI1 transcription axis involved in cancer drug resistance, overall survival and therapy prognosis in lung cancer patients.","description":"Several homeobox-related gene (HOX) transcription factors such as mesenchyme HOX-2 (MEOX2) have previously been associated with cancer drug resistance, malignant progression and/or clinical prognostic responses in lung cancer patients; however, the mechanisms involved in these responses have yet to be elucidated. Here, an epigenomic strategy was implemented to identify novel MEOX2 gene promoter transcription targets and propose a new molecular mechanism underlying lung cancer drug resistance and poor clinical prognosis. Chromatin immunoprecipitation (ChIP) assays derived from non-small cell lung carcinomas (NSCLC) hybridized on gene promoter tiling arrays and bioinformatics analyses were performed, and quantitative, functional and clinical validation were also carried out. We statistically","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Sep","modification":"2026-05-03T19:04:37.415Z","creation":"2019-03-27T02:57:42Z"},"accession":"S-EPMC5620156","cross_references":{"pubmed":["28978016"],"doi":["10.18632/oncotarget.17715"]}}